EHA 2018 Annual Congress Highlights in Multiple Myeloma

EHA Overview from Joshua Richter, MD Key findings from EHA and trials to watch Venetoclax monotherapy and combined with dexamethasone for t(11;14) RRMM Run Time: 13:33 Begin

EHA Highlights from Paul G. Richardson, MD Phase 2 ELOQUENT-3: Elotuzumab plus pomalidomide-dexamethasone vs pom-dex for RRMM Phase 3 OPTIMISMM: Pom-bortezomib-low‐dose dex vs bort-low-dose dex in lenalidomide-exposed RRMM Phase 1b: Isatuximab plus pom-dex in RRMM Run Time: 19:33 Begin

EHA Highlights from Saad Z. Usmani, MD, FACPP INSIGHT MM: Largest global prospective, observational MM study Run time: 5:45 Begin

EHA Highlights from Maria-Victoria Mateos, MD, PhD Phase 3 A.R.R.O.W.: Once-weekly vs twice-weekly carfilzomib plus dex in RRMM MMY1001: Daratumumab-carfilzomib-dex in len-refractory RRMM Run time: 11:27 Begin

Bonus Highlight – (not required for credit)

View Highlight